A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

BACKGROUND: Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. Preclinical studies demonstrated that indoximod combined with chemotherapy was synergistic in a mouse model of breast cancer. A phase I 3+3 trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Soliman, Hatem H., Jackson, Erica, Neuger, Tony, Dees, E. Claire, Harvey, R. Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N., Link, Charles, Sullivan, Daniel M., Antonia, Scott
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226672/
https://ncbi.nlm.nih.gov/pubmed/25327557
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados